In line with this finding, Schalper et al. 2019 demonstrated that a neoadjuvant therapy of the PD-1 inhibitor nivolumab activates GBM immune microenvironment in a single-arm phase II clinical trial (NCT02550249) [15]. Here, PDCD1 is linked to glioblastoma.